Loading
Latest filing published 07 May 2026 for HighTide Therapeutics, Inc. - B.
Not enough buy signals with a settled T+90 horizon to measure a track record yet.
No signal scores available.
LIU Liping (chief executive) discloses dealings in 2 companies, chiefly HighTide Therapeutics, Inc. - B and Guoen Holdings Ltd. Over a trading history stretching from 20 October 2023 to 30 April 2026, the count stands at 9 filings.
On the market, this insider has only sold: 2 sales. The amount is not disclosed for 2 filings. In 2026 alone, the filings show no purchases and 1 sale.
The latest filing, published on 7 May 2026, reports an open-market sale in HighTide Therapeutics, Inc. - B. Filings reach the HKEX feed a median of 7 days after the trade. This delay matters because a trade only becomes useful information once it is public. A sale on its own says little: insiders also sell to pay tax, fund a purchase or diversify. Source: insider filings from HKEX. Past trades are no guide to future returns.
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
2 of 2 declarations